Levetiracetam is under clinical development by UCB and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Levetiracetam’s likelihood of approval (LoA) and phase transition for Alzheimer’s Disease took place on 28 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Levetiracetam Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Levetiracetam overview

Levetiracetam (Keppra, Kepcet, E Keppra) is an anticonvulsant and antiepileptic agent. It is formulated as tablets, film-coated tablets, solution for oral administration and injection solution, solution concentrate for intravenous route of administration. Keppra is indicated for the treatment of epilepsy, generalized seizures, generalized tonic-clonic seizure, myoclonic seizures, partial seizure (including secondary generalized seizure) and also for partial seizures in children. Levetiracetam injection solution is indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizure (including secondary generalized seizure) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. It is used as an alternative therapy for levetiracetam oral formulation in patients who are temporarily unable to be administered orally.

The drug candidate is under development for the treatment of Alzheimer's disease. It was also under development for postherpetic neuralgia, neuroleptic-induced tardive dyskinesia, levodopa-induced dyskinesia, alcohol dependence, uncontrolled generalized tonic-clonic (GTC) seizures and panic disorder.

UCB overview

UCB is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company’s marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn’s disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson’s disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Brussels-Capital Region, Belgium.

Quick View Levetiracetam LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Levetiracetam
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Developers
  • Sponsor Company: UCB
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.